Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales
Executive Summary
Exelixis is looking to get its kidney cancer drug Cabometyx approved for hepatocellular carcinoma as well, but the therapy's long-term success is reliant on combinations with checkpoint inhibitors